Author: news_poster
Posted: Fri Feb 24, 2012 3:00 am
Source: MTRAC
Area: Evidence > Drug Specific Reviews
MTRAC, the Midlands Therapeutics Review & Advisory Committee, has issued its latest Commissioning Guidance report, covering buprenorphine transdermal patch (BuTrans and Transtec) for the treatment of chronic non-cancer pain (the committee did not consider guidance for the use of transdermal buprenorphine for cancer-related pain because this was considered to be restricted to specialist care).
The report summarises the clinical trial data for buprenorphine transdermal patches for chronic non-cancer pain and concludes that it is suitable for restricted prescribing under defined conditions. Buprenorphine should be initiated by a specialist or a specialist pain management service, given the range of alternative treatments…
Source: MedWorm Query: Buprenorphine
MedWorm.com provides a medical RSS filtering service. Data from over 6000 medical RSS feeds is collected and output via different categories. This feed contains the latest items on MedWorm Query: Buprenorphine